Logo image of AVEO

AVEO PHARMACEUTICALS INC (AVEO) Stock Fundamental Analysis

NASDAQ:AVEO - US0535883070 - Common Stock

15 USD
0 (0%)
Last: 1/19/2023, 8:09:51 PM
15 USD
0 (0%)
After Hours: 1/19/2023, 8:09:51 PM
Fundamental Rating

3

Taking everything into account, AVEO scores 3 out of 10 in our fundamental rating. AVEO was compared to 542 industry peers in the Biotechnology industry. AVEO may be in some trouble as it scores bad on both profitability and health. AVEO shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVEO has reported negative net income.
In the past year AVEO has reported a negative cash flow from operations.
AVEO Yearly Net Income VS EBIT VS OCF VS FCFAVEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

The profitability ratios for AVEO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVEO Yearly ROA, ROE, ROICAVEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 500 1K

1.3 Margins

The Gross Margin of AVEO (87.81%) is better than 91.08% of its industry peers.
The Profit Margin and Operating Margin are not available for AVEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVEO Yearly Profit, Operating, Gross MarginsAVEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

AVEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVEO has more shares outstanding than it did 1 year ago.
AVEO has a worse debt/assets ratio than last year.
AVEO Yearly Shares OutstandingAVEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
AVEO Yearly Total Debt VS Total AssetsAVEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.48, we must say that AVEO is in the distress zone and has some risk of bankruptcy.
AVEO has a worse Altman-Z score (-4.48) than 68.86% of its industry peers.
A Debt/Equity ratio of 0.94 indicates that AVEO is somewhat dependend on debt financing.
AVEO has a worse Debt to Equity ratio (0.94) than 82.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC9.35%
AVEO Yearly LT Debt VS Equity VS FCFAVEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M

2.3 Liquidity

AVEO has a Current Ratio of 2.37. This indicates that AVEO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.37, AVEO is doing worse than 78.87% of the companies in the same industry.
A Quick Ratio of 2.35 indicates that AVEO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.35, AVEO is doing worse than 77.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.35
AVEO Yearly Current Assets VS Current LiabilitesAVEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

AVEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
AVEO shows a strong growth in Revenue. In the last year, the Revenue has grown by 269.46%.
The Revenue has been growing by 76.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%

3.2 Future

The Earnings Per Share is expected to grow by 40.39% on average over the next years. This is a very strong growth
Based on estimates for the next years, AVEO will show a very strong growth in Revenue. The Revenue will grow by 75.28% on average per year.
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
AVEO Yearly Revenue VS EstimatesAVEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AVEO Yearly EPS VS EstimatesAVEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVEO. In the last year negative earnings were reported.
AVEO is valuated quite expensively with a Price/Forward Earnings ratio of 27.40.
96.09% of the companies in the same industry are more expensive than AVEO, based on the Price/Forward Earnings ratio.
AVEO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.48.
Industry RankSector Rank
PE N/A
Fwd PE 27.4
AVEO Price Earnings VS Forward Price EarningsAVEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVEO Per share dataAVEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AVEO's earnings are expected to grow with 40.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.26%
EPS Next 3Y40.39%

More info and screens

0

5. Dividend

5.1 Amount

AVEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVEO PHARMACEUTICALS INC

NASDAQ:AVEO (1/19/2023, 8:09:51 PM)

After market: 15 0 (0%)

15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2022-11-07/amc
Earnings (Next)03-13 2023-03-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner Change0%
Market Cap521.45M
Analysts50
Price Target15.3 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.92%
Min EPS beat(2)15.97%
Max EPS beat(2)49.87%
EPS beat(4)3
Avg EPS beat(4)18.91%
Min EPS beat(4)-18.6%
Max EPS beat(4)49.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)1.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.59%
EPS NY rev (1m)0%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.4
P/S 5.53
P/FCF N/A
P/OCF N/A
P/B 18.08
P/tB 18.08
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)0.55
Fwd EY3.65%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS2.71
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.81%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.35
Altman-Z -4.48
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A
EBIT growth 1Y56.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.21%
OCF growth 3YN/A
OCF growth 5YN/A